FDA Issues Recommendations for Cell and Gene Therapy Makers

The FDA is calling for risk assessments by cell and gene therapy (CGT) manufacturers to minimize the potential for transmitting the SARS-CoV-2 virus through their products, according to a new straight-to-final guidance released yesterday.
Source: Drug GMP Report